Hemodialysis Access Surveillance, Failure, Central Venous Disease, and Complications

61.1Monitor function before anatomy

Surveillance of hemodialysis access is not an exercise in cataloging every stenosis. It is a longitudinal clinical decision process: determine whether the access is delivering dialysis reliably, whether a developing problem threatens usable access, and whether intervention will improve a patient-relevant outcome. The practical frame is the patient’s overall access life-plan, current dialysis dependence, prior access history, remaining venous options, cardiac reserve, infection risk, and likelihood that an intervention will preserve rather than consume future options. Modern guideline framing places access maintenance and complication management within an individualized ESKD life-plan rather than a device-centered algorithm, and this is the correct mental model for the surgeon reviewing a fistula or graft at the bedside KDOQI clinical practice 2019.

The first surveillance tool is clinical monitoring. The surgeon should ask whether the dialysis unit is seeing difficult cannulation, prolonged bleeding after needle removal, falling delivered dialysis, recurrent clotting, arm swelling, new collateral veins, aneurysmal change, pain, hand ischemia, infection, or an access that “sounds different.” Physical examination should define the pulse, thrill, bruit, collapse with arm elevation, augmentation with inflow compression, aneurysm or pseudoaneurysm, skin quality, edema, and distal perfusion. This information determines whether the next step is reassurance, cannulation retraining, duplex ultrasound, fistulography with intent to treat, urgent thrombectomy, surgical revision, catheter planning, or access abandonment UK Kidney Association 2025 · KDOQI clinical practice 2019.

Function should be interpreted before anatomy. A stenosis seen on duplex or fistulography is clinically meaningful when it explains a functional abnormality, predicts imminent access loss in context, or alters the safety of cannulation or dialysis delivery. Conversely, an anatomic narrowing without clinical dysfunction should not automatically trigger angioplasty, because randomized evidence has not established routine surveillance-driven pre-emptive correction as beneficial for all stenoses. A Cochrane review found evidence insufficient to support routine technology-based screening followed by pre-emptive correction compared with intervention deferred until clinical dysfunction AVF 2016.

The decision to escalate is therefore triggered by clinical change rather than by a single image. For a mature access, escalation is appropriate when dialysis delivery deteriorates, cannulation becomes unreliable, post-dialysis bleeding is prolonged, thrombosis occurs, the access develops symptomatic edema or ischemia, skin overlying an aneurysm becomes threatened, or infection is suspected. Guideline statements support clinical monitoring with selective technology-based surveillance rather than universal routine imaging-driven intervention, reflecting the lack of randomized benefit for routine pre-emptive treatment in otherwise functioning accesses UK Kidney Association 2025 · KDOQI clinical practice 2019.

Surveillance findings also shape later treatment planning. A recurrent venous outflow lesion after repeated angioplasty suggests that the next procedure should be planned rather than improvised: define inflow, cannulation zone, target lesion, central outflow, and remaining surgical options before another balloon is inflated. A thrombosed access should be understood as a circuit failure with an underlying culprit lesion until proven otherwise; durable salvage requires clot removal and treatment of the stenosis that caused thrombosis Endovascular management thrombosed 2022. Documentation should record the functional trigger, physical findings, imaging modality, culprit lesion, treatment performed or deferred, and the planned follow-up interval or dialysis-unit warning signs KDOQI clinical practice 2019.

Complication surveillance must include problems outside the stenosis-thrombosis pathway. AV access complications include infection, neuropathy, aneurysm, pseudoaneurysm, steal syndrome, venous hypertension, and high-output cardiac failure. The patient approaching exhaustion of upper-extremity options deserves especially deliberate decision-making: a technically feasible intervention is not always the best choice if it accelerates loss of cannulation zone, worsens central venous hypertension, or compromises future access sites KDOQI clinical practice 2019 · AVF 2017.

Access type and access timing affect the clinical stakes of surveillance. Catheter users have higher all-cause mortality, fatal infection, and cardiovascular event risk than fistula users, and graft users have higher mortality and fatal infection risk than fistula users in meta-analysis. These data do not mean that every patient must have a fistula at any cost, but they do explain why maintaining a usable, complication-free permanent access is a central surgical responsibility Associations between Hemodialysis 2013. Earlier access creation before dialysis initiation has also been associated with lower subsequent mortality, supporting timely access planning before catheter dependence becomes prolonged Association between Timing 2024.

Not all postoperative findings require intervention. One-stage and two-stage brachiobasilic fistula creation had no statistically significant difference in maturation success, postoperative hematoma, wound infection, or steal syndrome in meta-analysis, reinforcing that surveillance after transposition should focus on the individual patient’s maturation, wound status, cannulation readiness, and complications rather than assuming one operative strategy mandates a different surveillance philosophy AVF 2015. When complications do occur, the surgeon should distinguish problems that threaten access use or patient safety from those that can be observed while cannulation practice, dialysis prescription, or follow-up imaging is adjusted AVF 2017.

Medication decisions after access failure should be individualized and modest in expectation. In a retrospective prosthetic graft declot cohort, median thrombosis-free survival was longer among patients receiving single or dual antiplatelet therapy than among those without antiplatelet therapy, but multivariable analysis did not show a statistically significant protective effect and bleeding events occurred. Antiplatelet therapy may be considered in selected patients after reviewing bleeding risk, access history, and competing indications, but it should not substitute for identifying and treating the mechanical cause of graft thrombosis AVG 2023.

61.2Treat dysfunction, not every narrowing

A malfunctioning access should be classified clinically before it is treated. A practical classification separates thrombotic events, nonthrombotic flow-related dysfunction, and infectious complications. This distinction prevents the common error of treating all failures as simple stenoses: thrombosis requires clot management and culprit-lesion treatment, flow dysfunction requires assessment of inflow, anastomosis, cannulation zone, outflow, and central veins, and infection requires source control and protection of the patient before any access-preservation ambition ACR appropriateness criteria 2023.

For nonthrombotic dysfunction, the central question is whether the narrowing explains the problem. A stenosis associated with difficult cannulation, inadequate dialysis delivery, abnormal access examination, prolonged bleeding, recurrent alarms, or swelling is a therapeutic target. A narrowing discovered incidentally in a clinically functioning circuit is not automatically a target, because routine technology-based surveillance followed by pre-emptive correction has not been proven to improve patient-relevant outcomes across the access population UK Kidney Association 2025 · AVF 2016.

When intervention is indicated, conventional angioplasty remains the default treatment for most stenoses. The operative discipline is to define the whole circuit, cross the lesion safely, prepare the lesion adequately, and reassess function after treatment rather than simply achieving an angiographic appearance. Digital subtraction angiography is commonly reserved for patients who are progressing to intervention, while ultrasound remains a frequent first-line modality because it is accessible, avoids contrast, and can characterize inflow and outflow abnormalities AVF 2021 · Imaging Vascular Access. 2017.

Drug-coated balloons have a role in selected dysfunctional AVF stenoses, but the evidence is heterogeneous and should be explained accurately. The Lutonix AV randomized trial reported better target-lesion primary patency with drug-coated versus uncoated balloon angioplasty at 9 months and one-year follow-up, with noninferiority safety met at each interval and no mortality difference between groups AVF 2020. The AcoArt Orchid trial similarly reported higher 6-month and 12-month target-lesion primary patency after paclitaxel drug-coated balloon treatment following high-pressure predilation Drug-Coated Balloon Angioplasty 2024.

Other analyses have been less uniformly positive. A meta-analysis of 11 randomized trials found no significant difference in target-lesion primary patency at 6 or one-year follow-up and similar procedure-related complication rates between drug-coated and conventional balloons Drug-coated balloon 2020. Another 14-trial meta-analysis in dysfunctional AVFs found no significant differences in target-lesion primary patency at 3, 6, 9, or one-year follow-up, with similar technical success and all-cause mortality AVF 2022. In contrast, a more recent meta-analysis found drug-coated balloons superior for 6-month and 12-month target-lesion primary patency without a mortality difference AVF 2023.

The surgeon should therefore use drug-coated balloons as part of a lesion- and patient-specific strategy rather than as a reflex. A single-center cohort reported AVF primary patency of 85.9%, 64.1%, and 34.1% at 6, 12, and 18 months after 4-cm drug-coated balloon angioplasty, with lesion length greater than 4 cm, tandem stenosis, and thrombosis independently predicting inferior primary patency AVF 2025. These predictors are clinically useful: a short recurrent target lesion in a functioning access is a different problem from a thrombosed circuit with tandem lesions and long-segment disease Endovascular management thrombosed 2022.

Thrombosed circuits require urgency, completeness, and realism. Endovascular thrombectomy combines clot removal with treatment of the underlying culprit stenosis using mechanical devices and angioplasty balloons; stent grafts are generally reserved for resistant or recurrent stenoses or for control of extravasation after rupture Endovascular management thrombosed 2022. A scoop-thrombectomy series for anastomotic AVF thrombosis reported high clinical success, no major complications, low minor complication rates, and favorable 3-, 6-, and 12-month primary patency after thrombectomy plus underlying-stenosis angioplasty, illustrating the principle that thrombectomy is incomplete unless the culprit stenosis is treated AVF 2022.

Prosthetic graft venous anastomotic stenosis is one setting where stent graft evidence is particularly important. In a multicenter randomized trial of prosthetic AVG venous anastomotic stenosis, stent graft plus balloon angioplasty achieved higher 6-month treatment-area patency, access-circuit patency, and freedom from subsequent interventions than balloon angioplasty alone AVG 2010. Practice reviews support stent and stent-graft use at venous anastomoses, for selected outflow lesions, graft pseudoaneurysms, cephalic arch disease, and selected central venous stenoses, while maintaining angioplasty as the default for most stenotic lesions Stent Stent-Graft Use 2016.

Cephalic arch disease deserves special caution because repeated angioplasty can provoke rupture, recoil, or rapid recurrence. In a small series of recalcitrant cephalic-arch stenosis or post-venoplasty rupture, undersized stent grafts with a stent-to-vessel diameter ratio below 1 were associated with higher primary stent and access patency, fewer reinterventions, and less lateral edge stenosis than size-apposed stent grafts; increasing stent-to-vessel ratio was independently associated with edge stenosis Undersized stent graft 2020. The practical lesson is not to oversimplify stent-graft sizing in the cephalic arch, where edge behavior and future cannulation implications matter.

Cannulation practice is part of access preservation. A meta-analysis comparing buttonhole and rope-ladder cannulation found that buttonhole cannulation increased bacteremia and did not improve primary patency or reduce thrombosis or intervention frequency. Rope-ladder cannulation should therefore remain the safer default unless a specific patient-centered reason supports an alternative plan, and any buttonhole program should be scrutinized for infection prevention, staff consistency, and early bacteremia signals Cannulation Technique Vascular 2023.

Steal risk should be considered before and after intervention. A meta-analysis of preventive operative techniques for dialysis access-associated steal syndrome found DASS associated with both AVF and AVG procedures and favored radiocephalic and distal endovascular AVF configurations in high-risk patients; preventive and corrective strategies included DRIL, extension techniques, MILLER, and proximalization of arterial inflow Dialysis Access-Associated Steal 2023. In practice, a patient with pain, neurologic symptoms, tissue loss, or distal hypoperfusion requires assessment of both access flow and distal arterial perfusion before repeated outflow procedures increase access efficiency at the expense of the hand.

Lower-extremity catheter access may be appropriate when upper-extremity access options are exhausted or unsafe. A tunneled femoral dialysis catheter is not a first-line substitute for durable access, but practical reviews describe indications, contraindications, and technique for femoral tunneled catheters when upper-extremity access and central venous routes are limited Tunneled femoral dialysis 2021. The decision should be documented as a bridge, a salvage strategy, or a palliative access plan, with attention to remaining venous options and the patient’s overall access life-plan KDOQI clinical practice 2019.

61.3Central outflow can explain repeat failure

Central venous disease should be suspected when access dysfunction is recurrent, anatomically discordant, or accompanied by arm swelling, venous hypertension, chest-wall collaterals, difficult cannulation, prolonged bleeding, or repeated outflow restenosis. The surgeon should especially assess patients with prior or current central venous catheters, pacemaker or pacing-wire exposure, and high-flow upper-extremity access. Contemporary reviews attribute central venous stenosis in hemodialysis largely to indwelling catheters and pacemaker wires, and prevention is framed around minimizing catheter exposure Central vein stenosis 2023.

Central outflow assessment changes management because a peripheral angioplasty cannot compensate for untreated central venous obstruction. In a large cohort of patients starting hemodialysis, central venous stenosis was diagnosed in 4.3% at a median dialysis vintage of 2.9 years; among patients with catheter history, incidence increased with prior catheter count. This supports a low threshold to examine central outflow in patients with catheter exposure and recurrent access dysfunction, especially before creating or revising ipsilateral access Central Venous Stenosis 2019.

The prevalence and clinical expression of central venous disease vary by population and ascertainment. Venous thoracic outlet syndrome in hemodialysis arises from extrinsic compression at the costoclavicular triangle compounded by distal AV access flow. Reported central venous stenosis prevalence ranges from 7% to 40% in catheter-dependent dialysis patients and from 19% to 41% in patients with prior catheter history, and approximately half may be asymptomatic at presentation Venous thoracic outlet 2023.

The history should identify prior internal jugular, subclavian, femoral, and tunneled catheters; pacemaker or defibrillator leads; prior central venous interventions; ipsilateral arm swelling; facial or breast swelling; collateral veins; access flow changes; and prior failures of angioplasty in the cephalic arch, axillary, subclavian, or brachiocephalic outflow. The examination should compare both arms, inspect chest-wall collaterals, assess access pulsatility and thrill, and document whether edema is localized or severe enough to impair cannulation or wound healing Central vein stenosis 2023 · Venous thoracic outlet 2023.

Imaging should be chosen according to the clinical question. Duplex ultrasound is useful for peripheral access evaluation but may be limited centrally; fistulography or venography is often required when central disease is suspected and intervention is contemplated. ACR guidance treats fistula malfunction through separate variants that include diagnostic imaging, clinical consultation, percutaneous intervention, and surgical intervention, reinforcing that central evaluation should be linked to the presenting malfunction rather than performed as an isolated image ACR appropriateness criteria 2023.

Management of central venous stenosis is primarily endovascular when symptoms or access dysfunction justify treatment. Contemporary reviews frame angioplasty as first-line therapy, with stenting for elastic recoil or recurrent lesions, while noting that no consensus exists on optimal patency strategy Central vein stenosis 2023. In a single-center cohort of central venous stenosis in maintenance hemodialysis, all patients had prior catheter or pacemaker exposure, brachiocephalic stenosis was more frequent than subclavian stenosis, and patients with more elastic recoil were assigned to sequential percutaneous transluminal stenting rather than angioplasty alone PTS 2024.

The decision to treat central disease should be documented with particular care. The note should state the clinical indication, prior catheter or device exposure, access side and type, central lesion location, symptom burden, whether elastic recoil or recurrence was present, whether angioplasty or stenting was selected, and how the decision affects future access planning. This documentation matters because a stent across a central venous segment may preserve the current circuit but constrain future surgical and endovascular options Central vein stenosis 2023 · Stent Stent-Graft Use 2016.

Central disease is also a health-equity and risk-stratification issue. In a fistulogram review of ESKD patients with dysfunctional access, central venous stenosis prevalence was similar between Black and White patients, but severe stenosis greater than 70% was more frequent in White patients; central venous stenosis was associated with central venous catheter use and cardiovascular disease in unadjusted analysis and with diabetes in adjusted analysis Prevalence Central Venous 2023. The practical response is not race-based treatment, but consistent documentation of catheter exposure, comorbidity, lesion severity, and access consequences.

Central venous thoracic outlet compression is a distinct pattern because the lesion may be driven by anatomy, access flow, and repeated endovascular injury. In hemodialysis-related venous thoracic outlet syndrome, extrinsic costoclavicular compression is compounded by distal AV access flow, and many patients may present without obvious symptoms until access dysfunction or venous hypertension emerges Venous thoracic outlet 2023. Repeated angioplasty without recognizing the compressive mechanism risks serial restenosis and progressive loss of central venous options.

Catheter minimization remains the most important preventive principle. Meta-analysis shows that catheter access is associated with higher all-cause mortality, fatal infection, and cardiovascular events compared with fistula access, and central venous stenosis literature links catheter history and catheter count to subsequent central venous disease Associations between Hemodialysis 2013 · Central Venous Stenosis 2019. The surgeon’s contribution is timely permanent access planning, deliberate catheter-site selection, and avoidance of unnecessary central venous instrumentation KDOQI clinical practice 2019 · Central vein stenosis 2023.

61.4Clinical integration, follow-up, and evidence boundaries

The mature access program should integrate bedside monitoring, dialysis-unit feedback, selective imaging, timely intervention, and explicit follow-up. Ultrasound can characterize early and late AVF complications, including inflow and outflow stenosis, pseudoaneurysm, hematoma, infection, and intimal hyperplasia, using color Doppler and pulse-wave Doppler with high-resolution transducers; phlebography remains the diagnostic gold standard when ultrasound is nondiagnostic AVF 2021. This supports a practical sequence: clinical abnormality first, targeted ultrasound when it will answer the question, and fistulography when intervention is likely or ultrasound cannot define the problem Imaging Vascular Access. 2017.

Imaging should not become a substitute for clinical judgment. Ultrasound is commonly favored because it is accessible, lower cost, and avoids contrast; digital subtraction angiography is generally reserved for cases progressing to intervention; MRI is constrained by cost and acquisition time; and CT is a problem-solving tool in complex cases Imaging Vascular Access. 2017. The surgeon should select the modality that will change management: inflow stenosis, outflow stenosis, pseudoaneurysm, infection, suspected central obstruction, or operative planning each requires a different question to be answered AVF 2021.

Follow-up after intervention should document both technical and functional outcomes. Technical success alone is insufficient; the access must be usable, cannulable, and capable of delivering dialysis without recurrent alarms, bleeding, swelling, or thrombosis. Drug-coated balloon trials commonly use target-lesion primary patency and safety endpoints, such as the IN.PACT AV trial’s 6-month target-lesion primary patency endpoint and 30-day serious-adverse-event noninferiority safety framework, but clinical practice must translate those endpoints into dialysis-unit function and patient symptoms KDOQI clinical practice 2019 · AVF 2020.

After angioplasty, the surgeon should communicate the treated lesion, residual stenosis if relevant, complications, cannulation instructions, and recurrence warning signs to the dialysis unit. If the lesion was long, tandem, thrombosed, central, cephalic arch-related, or recurrent, follow-up should be more deliberate because these features predict or imply a higher likelihood of restenosis or repeat intervention AVF 2025 · Central vein stenosis 2023 · Undersized stent graft 2020. When the procedure involved thrombectomy, the record should identify the culprit stenosis and the method used to restore flow, because thrombectomy without durable lesion treatment invites early rethrombosis Endovascular management thrombosed 2022.

Stent grafts should be used with a clear indication and a plan for future access. Randomized trial evidence supports stent grafts at prosthetic graft venous anastomotic stenosis, where 6-month treatment-area patency, access-circuit patency, and freedom from subsequent interventions were higher than with balloon angioplasty alone AVG 2010. Reviews also support stent and stent-graft use in selected outflow veins, graft pseudoaneurysms, cephalic arch lesions, and selected central venous stenoses, while angioplasty remains the default treatment for most access stenoses Stent Stent-Graft Use 2016.

Complication management must remain patient-centered. Infection is not merely an access problem; it is a threat to the patient and to future access options. Aneurysm and pseudoaneurysm management should consider skin integrity, cannulation safety, infection, and available cannulation zones. Neuropathy and ischemia require careful evaluation because improving access flow or outflow may worsen symptoms in selected patients. Reviews of access complications emphasize infectious and noninfectious problems, including neuropathy, aneurysm, and high-output cardiac failure, especially in patients with multiple prior complications and limited remaining options AVF 2017.

The evidence boundary around drug-coated balloons should be explicit in surgical decision-making. Individual randomized trials and some contemporary analyses support improved target-lesion patency in AVF stenosis, while other meta-analyses have found no significant benefit at several time points and similar safety outcomes AVF 2023 · AVF 2022 · Drug-coated balloon 2020 · Drug-Coated Balloon Angioplasty 2024 · AVF 2020. A balanced practice is to reserve drug-coated balloons for selected dysfunctional lesions where improved target-lesion patency would meaningfully reduce reintervention, while recognizing lesion length, tandem disease, and thrombosis as adverse predictors AVF 2025.

The evidence boundary around surveillance is equally important. Clinical monitoring is strongly embedded in guideline-based care, but routine technology-based surveillance with pre-emptive correction of every stenosis has not shown sufficient evidence of benefit to justify indiscriminate intervention UK Kidney Association 2025 · AVF 2016. A well-run access program therefore avoids two extremes: neglecting early clinical dysfunction until thrombosis occurs, and repeatedly treating incidental anatomy without a functional indication KDOQI clinical practice 2019.

Special populations and unusual complications should be handled by principle rather than by extrapolation. Ultrasound reviews in newborn vascular access emphasize pre-implantation imaging for anatomical variation, vessel caliber, depth, course patency, adjacent structures, intraluminal thrombus, and post-catheter monitoring of the internal jugular vein; although this is not adult hemodialysis surveillance, it reinforces the general surgical principle that imaging should define anatomy, risk, and follow-up consequences before vascular instrumentation Advantages use ultrasound 2024. Similarly, iatrogenic tibial arteriovenous fistula after distal Fogarty passage in calcified tibial vessels illustrates that thrombectomy tools can create vascular complications when used in diseased distal arteries AVF 2021.

Failure should prompt a structured reassessment rather than resignation. After recurrent dysfunction, the surgeon should review whether the failure is due to inflow disease, anastomotic stenosis, cannulation-zone injury, venous outflow stenosis, central venous obstruction, access flow competing with distal perfusion, infection, or patient-level factors such as limited remaining sites. Access preservation is valuable because catheter dependence carries higher mortality, fatal infection, and cardiovascular risk than fistula access, but preservation should not become repeated low-yield intervention when the circuit no longer serves the patient’s overall access life-plan KDOQI clinical practice 2019 · Associations between Hemodialysis 2013.

The final follow-up plan should be understandable to the patient, dialysis unit, and access team. It should state whether the access may be cannulated immediately or after a specified recovery plan, what signs require urgent contact, whether central venous disease or recurrent stenosis changes future access options, and whether a catheter bridge is temporary or likely to be long term. When access creation can be planned before dialysis initiation, earlier creation has been associated with lower all-cause mortality compared with late creation, reinforcing that surveillance and salvage are only one part of a broader access strategy that begins before catheter dependence KDOQI clinical practice 2019 · Association between Timing 2024.